Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Captain Jack who wrote (1045)	5/29/2002 2:17:41 PM
From: Skywatcher	Respond to of 1137

1:53PM Gilead Sciences breaks lower, too (GILD) 34.85 -3.10: Stock being mentioned as the latest casualty of the SG Cowen conference call on Hepatitis (see 13:00). We are hearing from traders that stock is falling victim to mention of Tenofovir-related liver toxicity discussed on the call. Again, Briefing.com is not on the call and, therefore, can't confirm the accuracy of these reports. GILD has plunged more than 1.5 pts over the past 30 minutes. I don't think this will hurt SCLN! CC

To: Captain Jack who wrote (1045)	7/16/2002 1:06:00 PM
From: Skywatcher	Read Replies (2) \| Respond to of 1137

ZADAXIN PRODUCES SUSTAINED RESPONSES IN MOST DIFFICULT TO TREAT HEPATITIS B PATIENTS San Mateo, CA, July 16, 2002 - SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) announced the results of a new study demonstrating that ZADAXIN® (thymalfasin, thymosin alpha 1) helps clear the hepatitis B virus in the most difficult to treat patients, those in the immune tolerant phase of this viral infection. Until this ZADAXIN clinical trial, virtually no treatment has been able to effectively cure hepatitis B in patients in the immune-tolerant phase of the viral infection. At the end of the 26 weeks of therapy and 52 weeks of follow-up observation, 15.6% of 32 hepatitis B immune-tolerant patients demonstrated a complete response to ZADAXIN therapy in combination with the nucleoside analogue famciclovir. By comparison, there were no responders among the 32 patients in each group that received either famciclovir monotherapy or placebo. OK....one more round from $2...... CC